Japanese pharma giant Takeda Pharmaceutical has agreed to sell its consumer healthcare business to Oscar A-Co KK, a company controlled by funds managed by The Blackstone Group and its affiliates (collectively Blackstone) for JPY 242 billion ($2.3 billion). The business being divested- Takeda Consumer Healthcare Company (TCHC) is focused on the consumer health care market […]
US-based pharma company Novavax and Takeda Pharmaceutical have joined forces for the development, manufacturing, and commercialization of NVX‑CoV2373, the former’s COVID‑19 vaccine candidate, in Japan. NVX‑CoV2373 is said to be a stable, prefusion protein produced by using the recombinant protein nanoparticle technology of Novavax. The coronavirus vaccine candidate also contains the company’s Matrix‑M adjuvant. Takeda […]
Takeda Pharmaceutical has secured extended approval for ADCETRIS (brentuximab vedotin) in the European Union to include the treatment of previously untreated systemic anaplastic large cell lymphoma (sALCL) in adult patients. The approval from the European Commission (EC) is for the combination of ADCETRIS with CHP (cyclophosphamide, doxorubicin, prednisone. It comes in the wake of a […]
Japan-based Takeda Pharmaceutical has agreed to sell a portfolio of 110 non-core over-the-counter (OTC) and prescription pharmaceutical products it sells in Europe along with a couple of manufacturing plants in Denmark and Poland to Orifarm Group for up to $670 million. As per the terms of the deal, Orifarm will pay nearly $505 million to […]
Takeda acquisition of PvP Biologics : Japanese pharma giant Takeda Pharmaceutical Company has acquired US-based celiac disease drug developer PvP Biologics in a deal worth up to $330 million. The Japanese pharma major exercised its option to acquire the US pharma company following the completion of a phase 1 proof-of-mechanism study of the latter’s investigational […]
ALTA-1L trial results : Takeda Pharmaceutical says that ALUNBRIG (brigatinib), its tyrosine kinase inhibitor (TKI), is continuing to show superiority over crizotinib in the phase 3 ALTA-1L trial. The Japanese pharma company released updated data from the late-stage trial involving adult patients having advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) who did […]
Takeda Pharmaceutical Company opened a new €130 million vaccine manufacturing plant in Germany at Singen to produce TAK-003, its dengue vaccine candidate. The Singen vaccine manufacturing facility will be used for the formulation, fill, finish and secondary packaging of the TAK-003 dengue vaccine candidate starting with the packaging line. The vaccine plant employs up to […]
The European Commission (EC) has officially expanded the approval of Takeda Pharmaceutical’s ADCETRIS (brentuximab vedotin) to include the treatment of previously untreated CD30+ Stage IV Hodgkin lymphoma in combination with AVD (Adriamycin, vinblastine, and dacarbazine) for adult patients. This new approval is a significant milestone for both Takeda and the Hodgkin lymphoma community, as it […]
In a landmark deal, Takeda Pharmaceutical Company has successfully completed its previously announced acquisition of Shire, an Irish biotech leader specializing in rare diseases, for a staggering $62 billion. This acquisition marks a major step in Takeda’s ongoing transformation into a global powerhouse in biopharmaceuticals, with an expanded footprint and a deeper focus on rare […]
PvP Biologics, a US-based pharmaceutical company, has recently begun two phase 1 clinical trials to assess the safety, tolerability, and pharmacodynamics of Kuma062, a promising new treatment for celiac disease. These trials are being conducted at Michigan Medicine at the University of Michigan and in Anaheim, involving approximately 80 adult participants. Kuma062 is engineered to […]